Waleria to feature aspurūs at upcoming SupplySide Connect

In a March 17, 2025 press release, women’s health ingredient supplier Waleria announced it would be featuring its Shatavari (Asparagus racemosus) root extract, aspurūs, at SupplySide Connect (formerly known as SupplySide East), taking place April 8–9, 2025 in Secaucus, New Jersey. The clinically studied ingredient, standardized to 5% Shatavarins, supports symptom relief for menopause. Waleria will be at Booth #609 at SupplySide Connect.

“Menopause is a pivotal stage in a woman’s life, and many are searching for safe, effective, and natural solutions to manage their symptoms – we can deliver that with aspurūs,” said Komal Baldwa, founder of Waleria, in the press release. “We know clinical research wins every time which is why we are committed to additional studies to support the ingredient – we are excited to showcase the ingredient at this year’s SupplySide Connect.”

A study is being conducted examining the synergistic effects of full-spectrum Shatavari extract for hormonal balance and other benefits.

In November of 2024, Waleria announced results from an in silico study on Shatavarins on female hormone receptors. Results from the computer models showed that the hormonal biomarkers were binding with the shatavarins at varying degrees, indicating a potential mechanism for relieving symptoms that are related to estrogen levels.

In a randomized controlled trial published in April 2024, 70 women were given shatavari root extract (250 mg twice daily) or placebo for eight weeks. Quality of life was measured on days 30 and 60, along with changes in symptoms. At the end of the study period, results indicated that compared to placebo, the extract relived symptoms of menopause, especially hot flashed and also night sweats, night flashes, anxiousness, fatigue, sleeplessness, mood swings, and urinary incontinence.

“Our study shows the potential of aspurūs in providing relief from major menopausal symptoms without the accompanying side effects often associated with conventional therapies,” Baldwa, had stated in an earlier press release. “This offers hope for women seeking effective and safe alternatives during this transformative phase of life. Additionally, it gives manufacturers an opportunity to formulate with a clinically studied lower dose ingredient efficacious in reducing major menopausal symptoms.”